Thursday, June 26, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Vutrisiran shows potential to become the new standard of care for rare heart disease

August 30, 2024
in Health
Reading Time: 3 mins read
0 0
A A
0
Home Health
Share on FacebookShare on Twitter



Vutrisiran considerably improved mortality, cardiovascular occasions and markers of illness development in sufferers with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), in accordance with late-breaking analysis offered in a Sizzling Line session at present at ESC Congress 2024.

ATTR is a progressive, deadly illness through which misfolded transthyretin protein accumulates as amyloid deposits in varied elements of the physique, typically damaging the guts. We investigated whether or not a novel RNA interference (RNAi) therapeutic, vutrisiran, which targets transthyretin manufacturing, might enhance scientific outcomes in sufferers with ATTR-CM and the outcomes have been very promising.”


Marianna Fontana, Principal Investigator, Professor, from College Faculty London, Royal Free Hospital, London, UK

HELIOS-B was a randomized, double-blind trial in sufferers with ATTR-CM (hereditary or wild-type) who had proof of cardiac amyloidosis by echocardiography and confirmed ATTR amyloid deposition. Sufferers have been randomized in a 1:1 ratio to vutrisiran 25 mg or placebo administered subcutaneously as soon as each 3 months for as much as 36 months. If the affected person was already receiving therapy with the illness stabiliser, tafamidis, this was continued.

The 2 main endpoints have been a composite of all-cause mortality and recurrent cardiovascular occasions when the final affected person reached month 33, assessed within the general inhabitants and in sufferers taking vutrisiran monotherapy (i.e. these not taking tafamidis at baseline). Secondary endpoints (assessed within the general inhabitants and in these on vutrisiran monotherapy) have been all-cause mortality as much as 42 months, change from baseline to 30 months in purposeful capability (6-minute stroll take a look at), high quality of life (Kansas Metropolis Cardiomyopathy Questionnaire General Abstract) and New York Coronary heart Affiliation (NYHA) class.

In whole, 655 sufferers have been recruited from 87 centres in 26 nations. The median age was 76.5 years and 92.5% have been male. Greater than three-quarters (77.6%) had coronary heart failure of NYHA class 2 and 40% have been taking tafamidis at baseline.

The trial met the first endpoints. Vutrisiran considerably lowered the chance of all-cause mortality and recurrent cardiovascular occasions by 28% within the general inhabitants (hazard ratio [HR] 0.72; 95% confidence interval [CI] 0.56-0.93; p=0.01) and by 33% within the monotherapy inhabitants (HR 0.67; 95% CI 0.49-0.93; p=0.016). In a prespecified subgroup evaluation, the composite of all-cause mortality and recurrent cardiovascular occasions was lowered by greater than 20% in sufferers on background tafamidis (HR 0.79; 95% CI 0.51-1.21).

Vutrisiran lowered all-cause mortality over 42 months by 36% within the general inhabitants (HR 0.64; 95% CI 0.46-0.90; p=0.01) and by 35% within the monotherapy inhabitants (HR 0.65; 95% CI 0.44-0.97; p=0.045) vs. placebo. Different secondary endpoints associated to purposeful capability, well being standing and high quality of life have been considerably improved with vutrisiran vs. placebo.

The vast majority of adversarial occasions have been delicate or reasonable with vutrisiran. Antagonistic occasions main to check drug discontinuation have been related within the vutrisiran (3.1%) and placebo (4.0%) teams.

Professor Fontana concluded: “Vutrisiran was extremely efficient and properly tolerated on this up to date inhabitants consultant of sufferers that we see in our clinics, with constant advantages no matter background tafamidis remedy. Our findings point out that vutrisiran has the potential to turn into the brand new commonplace of care. This trial can also be necessary as it’s the first to indicate the good thing about gene silencers in any kind of cardiomyopathy.”

Supply:

European Society of Cardiology (ESC)



Source link

Tags: carediseaseheartpotentialrareshowsstandardVutrisiran
Previous Post

Peach Cobbler with Cake Mix and Fresh Peaches

Next Post

Reimagine Care extends partnership with Memorial Hermann Health System

Related Posts

Common bacteria in mouth can help predict progression of head and neck cancer
Health

Common bacteria in mouth can help predict progression of head and neck cancer

June 26, 2025
Sleep deficiency worsens pain mechanisms in migraine sufferers
Health

Sleep deficiency worsens pain mechanisms in migraine sufferers

June 26, 2025
What VCs Have Learned About Health Tech in the Public Markets
Health

What VCs Have Learned About Health Tech in the Public Markets

June 26, 2025
Where a very preterm baby is born may affect survival odds and hospital time
Health

Where a very preterm baby is born may affect survival odds and hospital time

June 25, 2025
Prenatal air pollution exposure linked to higher childhood obesity risk
Health

Prenatal air pollution exposure linked to higher childhood obesity risk

June 25, 2025
The Hospital Word Has Become a Tale of the Haves and Have-Nots
Health

The Hospital Word Has Become a Tale of the Haves and Have-Nots

June 25, 2025
Next Post
Reimagine Care extends partnership with Memorial Hermann Health System

Reimagine Care extends partnership with Memorial Hermann Health System

CMS publishes FAQs for code G2211

CMS publishes FAQs for code G2211

WELL Health receives approval for M digital project

WELL Health receives approval for $44M digital project

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Easy Herb Grilled Vegetables – Sharon Palmer, The Plant Powered Dietitian
Diet & Fitness

Easy Herb Grilled Vegetables – Sharon Palmer, The Plant Powered Dietitian

by admin
June 20, 2025
0

Simple Herb Grilled Greens (Vegan, Gluten-Free, & Scrumptious!) Grilled greens are the final word aspect dish for anybody seeking to...

The 13 Best Crystals For Love & Relationships

The 13 Best Crystals For Love & Relationships

June 23, 2025
Top Dietitian Tips for Eating Healthy on Vacation Without Stress

Top Dietitian Tips for Eating Healthy on Vacation Without Stress

June 24, 2025
Bluebird Kids Health to Expand By Opening New Pediatric Clinics

Bluebird Kids Health to Expand By Opening New Pediatric Clinics

June 21, 2025
Inaccuracies found in key studies for blockbuster heart drug ticagrelor

Inaccuracies found in key studies for blockbuster heart drug ticagrelor

June 20, 2025
Hearty French Wild Rice Vegetable Soup

Hearty French Wild Rice Vegetable Soup

June 25, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In